Purdue Pharma L.P. Presents Data from Research Studies at American Pain Society 33rd Annual Scientific Meeting
STAMFORD, Conn., April 29, 2014 /PRNewswire/ -- Purdue Pharma L.P. will present results from a number of research studies at the American Pain Society (APS) 33rd Annual Scientific Meeting, April 30-May 3, 2014, in Tampa, Fla.
Following is a schedule of select poster presentations:
|
Title |
Authors |
Date / Time |
| A Single-Center, Randomized, Double-Blind Crossover Study to Evaluate the Abuse Potential, Pharmacokinetics, and Safety of Milled and Intranasally Administered Extended- Release Hydrocodone in Recreational Opioid Users |
Harris S, Colucci S, Perrino P, Kapil R, Geoffroy P, Hopyan T, Levy-Cooperman N |
Thursday, May 1 9:30 AM–11:00 AM |
| A Single-Center, Randomized, Double-Blind, Crossover Study to Evaluate the Abuse Potential, Pharmacokinetics, and Safety of Oral Milled and Intact Extended-Release Hydrocodone (HYD) Tablets in Recreational Opioid Users |
Harris S, Colucci S, Perrino P, Kapil R, Geoffroy P, Hopyan T, Levy-Cooperman N |
Friday, May 2 8:45 AM-10:15 AM
|
| Long-term Safety and Effectiveness of Once- daily, Single-entity, Abuse-deterrent Hydrocodone in Chronic Nonmalignant and Nonneuropathic Pain: Results of a Long-term Open-label Study |
Wen W, Taber L, Lynch SY, Munera C, Ripa SR |
Thursday, May 1 9:30 AM–11:00 AM |
| In Vitro Assessment of the Effects of Alcohol on the Release Rate of Hydrocodone Bitartrate from a Once-daily, Single-Entity, Hydrocodone Bitartrate Formulation |
Giordano J, Huang H, Kianto J |
Friday, May 2 8:45 AM-10:15 AM
|
| Comparison of the Risk of Opioid Overdose among Patients Prescribed Immediate-Release and Extended-Release Opioid Analgesics |
Coplan P, DeVeaugh-Geiss A, Kadakia A |
Thursday, May 1 9:30 AM–11:00 AM |
| Abuse-deterrent Opioid Analgesic Formulations: Technology, Evaluation, and Labeling |
Haddox D |
Friday, May 2, 2014 8:45 AM - 10:15 AM
|
| Impact of an opioid reformulation with abuse- deterrent properties on doctor-shopping |
Chilcoat H, Coplan PM, Sessler NE, Schultz Y, Yuan Y |
Friday, May 2, 2014 8:45 AM - 10:15 AM |
| Epidemiology of Conditions Associated with Pain and the Use of Analgesic and Non- Analgesic Treatments in Pediatrics |
Wallace L, Baldridge S, Matsuno R |
Thursday, May 1 9:30 AM – 11:00 AM |
| Neonatal Abstinence Syndrome in Commercially-insured and Medicaid Patients: Differences in Patient and Maternal Characteristics and Outpatient Treatment Patterns |
Wallace L, Harding B, Matsuno RK
|
Thursday, May 1, 9:30 AM – 11:00 AM |
About Purdue Pharma L.P.
Purdue Pharma L.P. and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.
| Contact: |
|
| James Heins |
Jennifer Soares |
| Senior Director, Public Affairs |
Senior Manager, Corporate Affairs & Communications |
| office: 203-588-8069 |
office: 203-588-7623 |
| mobile: 203-856-2121 |
mobile: 203-609-1746 |
| Email: [email protected] |
email: [email protected] |
SOURCE Purdue Pharma L.P.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article